Pharmaceutical

CTX-310 by CRISPR Therapeutics for Homozygous Familial Hypercholesterolemia (HoFH): Likelihood of Approval

CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Homozygous Familial Hypercholesterolemia (HoFH).

Jul 6, 2024 - 04:00
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Homozygous Familial Hypercholesterolemia (HoFH).
Read the original article

Tags:

Previous Article

CTX-310 by CRISPR Therapeutics for Heterozygous familial hypercholesterolemia (h...

Next Article

CTX-310 by CRISPR Therapeutics for Hypertriglyceridemia: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: European regulators endorse Casgevy, paving way for approval of CRISPR-based therapy

STAT+: European regulators endorse Casgevy, paving way ...

Dec 15, 2023

FDA grants RPDD to META Pharmaceuticals’ hyperoxaluria drug

FDA grants RPDD to META Pharmaceuticals’ hyperoxaluria ...

Aug 7, 2024

Opinion: I’m a biopharma supply chain specialist — and even I can’t find the Adderall I’m prescribed

Opinion: I’m a biopharma supply chain specialist — and ...

Apr 15, 2023